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ValidationPurpose: The aim of our study was an external validation of the extracranial prognostic score predicting
survival of patients with brain metastases receiving cranial irradiation on data from a single institution.
Materials and methods: A retrospective analysis of 524 patients with brain metastases treated with cranial
radiotherapy in a single tertiary center was performed. Three predictive scores were calculated and
assessed for their ability to discriminate prognostic groups: (i) The Recursive Partitioning Analysis
(RPA) score (available for 524 patients); (ii) the Diagnosis-Specific Graded Prognostic Assessment (DS-
GPA) score (464 patients); (iii) the extracranial score (EC-S) developed by Nieder et al. which is based
on serum albumin, lactate dehydrogenase (LDH) and the number of extracranial organs involved (157
patients). Discrimination of each score was assessed by Gönen & Heller’s concordance probability esti-
mate (CPE). The calibration was checked by comparing median survival estimates of each risk group with
the corresponding values of the datasets from which the scores were derived. Finally, a multivariable Cox
regression model was built by using the least absolute shrinkage and selection operator on a large num-
ber of variables including all three scores.
Results: With a CPE = 0.626 ± 0.022, the EC-S had the best discriminatory power. The EC-S also appeared
to be better calibrated and had the best ability to separate patients with a very poor prognosis: patients
with combination of low albumin, elevated LDH and more than 1 extracranial organ with metastatic
involvement had a median survival time of only 0.6 months (CI95% 0.1–1.1) and a hazard ratio for death
of 6.36 (2.67–15.14) compared to patients with no extracranial metastases and normal levels of albumin
and LDH. In the multivariable Cox model serum albumin, LDH, treatment modality, DS-GPA and EC-S
were retained as prognostic factors. An ad hoc combination of both DS-GPA and EC-S into a new score
was possible for 134 patients and indicated a slightly better discrimination (CPE = 0.636 ± 0.023) than
either DS-GPA or EC-S alone.
Conclusions: This study provides an independent validation of the prognostic EC-S which was the best
prognostic model for defining the patients who obviously did not benefit from radiation therapy of brain
metastases in terms of overall survival. The combination of the EC-S with the established DS-GPA score
resulted in a slight increase in discriminatory ability. The new EC-GPA score needs further validation in
larger patient cohorts.
 2019 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The development of appropriate patient selection criteria for
tumor specific treatment including chemo- and radiotherapy (RT)is the cornerstone of modern precision oncology. With regard to
life-threatening conditions such as brain-disseminated cancer it
is widely believed and anticipated that aggressive antitumor treat-
ment should be started as soon as possible to prolong survival and
maintain quality of life. However, it has long been recognized that
some patients will not derive any profit from active treatment
while other will do. In order to discriminate those patients
16 V. Lewitzki et al. / Clinical and Translational Radiation Oncology 16 (2019) 15–20potentially benefitting from antitumor therapy, several prognostic
scores such as the RTOG Recursive Partitioning Analysis (RPA) [1]
score or the Graded Prognostic Assessment (GPA) score [2] were
developed and validated [3,4]. Although offering a possibility to
separate the survival curves, i.e., identifying patient groups with
better and worse prognosis, these models have not sufficient pre-
dictive ability for deciding which patients will not derive sufficient
benefit from brain RT, which is important within the context of
counselling patients about their prognosis and treatment options.
It is known that several widely available and cheap blood tests
such as albumin and lactate dehydrogenase (LDH) can be used as
surrogate parameters in survival prediction [5,6]. The number of
extracranial organ systems involved has also been found to be an
independent and highly significant predictor of overall survival
[7,8]. The combination of those three parameters was used by Nie-
der et al. to develop a simple extracranial score (EC-S) as a reason-Table 1








































Number of brain metastases
One 143







Surgery + adjuvant RT or stereotactic radiosurgery 103
WBRT and others 421able addition to the aforementioned intracranial prognostic factors
helping to identify the patients with brain metastases with very
bad prognosis in whom best supportive care could be the best
choice [9]. The main goal of this study was an independent valida-
tion of the EC-S as a possible tool for predicting very limited sur-
vival and to compare it with the RPA and disease-specific GPA
(DS-GPA) scores.
2. Materials and methods
We extracted all available patient records referring to a diagno-
sis of brain metastases from the clinical RT software Mosaiq from
the Department of Radiation Oncology at the University hospital
Wuerzburg. Overall survival (OS) data from 524 patients treated
between 04.02.2008 and 08.11.2017 were available. Brain MRI
was obligatory as a part of staging for patients with primarily), Karnofsky performance score (KPS), whole brain radiotherapy (WBRT), radiotherapy
%
EC-S available (whole) EC-S available
64 46 41
93 54 59
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cases the clinical symptoms of brain metastases prompted cranial
imaging. In our clinic the vast majority of tumor patients receive
their treatment recommendation after discussion in interdisci-
plinary tumor boards. Further diagnostic work-up was performed
according to the advice of the tumor board and based basically
on national guidelines. Prognostic scores for each patient were
determined as originally described [1,2]. For calculating the EC-S
one point was counted for each elevated LDH, decreased albumin
and more than one extracranial site of metastatic involvement,
so that the final score ranged from 0 to 3 (3 indicating the worst
prognosis) [6].
Elevated LDHwas defined as above 250 U/l, and decreased albu-
min was defined as below 3.5 g/l according to the normal levels of
the local laboratory. LDH and albumin measurements were only
considered if taken within 2 weeks before the first fraction of RT.
Since both blood tests are not mandatory in our radiotherapy
department, only 157 out of 524 extracted patient records con-
tained information on all 3 extracranial prognostic parameters. In
contrast, the RPA score could be computed for all, and DS-GPA
score for 466 patients. Only 134 cases had both DS-GPA and EC-S
available. An overview of all relevant patient characteristics is
given in Table 1.
Actuarial survival from the first day of whole-brain (WB) or
other RT was calculated using the Kaplan-Meier method and com-
pared between different groups with the Log-rank test. Discrimina-
tion of each score was assessed by Gönen & Heller’s concordance
probability estimate (CPE) for the Cox model [10]. The concordance
probability is a general measure of discriminatory power of a non-
linear statistical model, with a probability of 0.5 indicating random
discrimination and 1 perfect discrimination. The calibration (exter-
nal validity) was checked by comparing median survival estimates
of each risk group with the corresponding values of the datasets
from which the scores were derived [11]. To determine the most
important prognostic factors in multivariable analysis, Cox regres-
sion was used. The following covariates from Table 1 were judged
as putatively important prognostic factors: treatment modality
(surgery + adjuvant RT or stereotactic radiosurgery/WBRT and
others), age (<65/65 years as used in the RPA score), gender, base-
line Karnofsky performance score (KPS; 70/>70), primary tumor
type (8 strata in total), presence of a molecular target with thera-
peutic relevance (yes/no), the number of extracranial organs
involved (0/1/>1), number of brain metastases (1/2 or 3/>3), serum
albumin (normal/decreased), LDH (normal/elevated), RPA score,
DS-GPA score and EC-S. Those variables were available for 140
patients of which 119 had died. Given the large number of vari-
ables compared to the number of events, we conducted variable
selection using the LASSO method which shrinks regression coeffi-
cients of less important variables to 0 and typically yields lowerTable 2
Results concerning the calibration and discrimination of the three scores applied to our d
models. Abbreviations used in the table:Confidence interval (CI), hazard ratio (HR), overal
RPA DS-GPA
1 2 3 3.5–4.0 2
N 133 262 129 28 9
# events 108 232 124 17 7
Median OS 8.38 5.16 1.77 12.91 7







HR 1 1.47 2.86 1 1
HR SE 0.12 1.14 0





Median OS in derivation dataset 7.1 4.2 2.3 16.7 (14.7–18.8) 9
Gönen & Heller’s CPE 0.5938 ± 0.0116 0.6110 ± 0.0123estimation variance than stepwise selection methods [12]. The
optimal penalty parameter k was determined based on 10-fold
cross validation and used for determining the most important pre-
dictor variables. These selected variables were then used to build a
new predictive model. We adhered to the TRIPOD criteria to assure
the transparence of our data presentation and analysis [13]. Statis-
tical analysis was performed with IBM-SPSS-25 and R version
3.5.0.3. Results
Most patients in the whole cohort had multiple brain metas-
tases (52%) and multiple extracranial metastases (52%) (Table 1).
The median KPS was 80, range 30–100. The most frequent primary
tumor was lung cancer (51.3%), followed by malignant melanoma
(14.3%) and breast cancer (12.7%). Albumin and LDH measure-
ments prior to RT were available for 165 and 260 patients respec-
tively, and 157 patients had both proteins measured. 132 events
were registered in this latter group and 25 cases were censored.
We used the DS-GPA (available for 464 patients with 410 events
and 54 censored cases) and RPA scores (available for 524 patients
with 464 events and 60 censored cases) as established reference to
compare with EC-S. The results are summarized in Table 2, and
Fig. 1 and Fig. 2 show the Kaplan-Meier survival curves for patients
stratified according to the DS-GPA score and EC-S, respectively.
Significant survival differences between all groups within each
prognostic score were seen except for groups 0 and 1 of the EC-S
(p = 0.974) which had similar median survival estimates (Table 2
and Fig. 2). However, the EC-S had the best discriminatory power
as judged by Gönen & Heller’s CPE. The EC-s was also the best score
for discriminating patients with a particularly poor prognosis,
since its worst prognostic class possessed the largest hazard ratio
(6.36) compared to the most favorable class. A comparison
between the median survival estimates of our cohort and those
of the datasets from which the different scores had been derived
revealed differences between the survival predictions for the
derivation datasets and our data. In this respect, the predictions
for classes 0, 2 and 4 of the EC-S appeared to be the best calibrated.
Using the LASSO method to build a multivariable prognostic
Cox model from our own data (140 patients and 119 events), the
following variables were selected: Treatment modality, Albumin,
LDH, DS-GPA score and EC-S. Using 5- or 20-fold instead of 10-
fold cross validation for finding the optimal LASSO penalty param-
eter did not change this variable selection result. The regression
coefficients of the final model fitted with these variables are given
in Table 3. The CPE of the final Cox model was 0.7230 ± 0.0212,
indicating a significant increase in discriminatory power compared
to every score on its own (Table 2).ataset. Gönen & Heller’s CPE is an estimate of the concordance probability of the Cox
l survival (OS).
EC-S
.5–3.0 1.5–2.0 0–1.0 0 1 2 3
2 154 190 15 69 60 13
5 135 183 9 56 54 13
.85 7.36 2.14 7.9 8.8 2.0 0.6
.74–14.26 5.16–9.36 1.81–2.86 3.9–
12
5.7–10.9 1.4–3.9 0.1–1.1
.64 2.26 4.12 1 1.05 2.31 6.36
.27 0.26 0.26 0.36 0.36 0.44






.6 (8.7–10.6) 5.4 (4.9–5.9) 3.1 (2.8–3.5) 9.0 3.5 2.3 0.7
0.6258 ± 0.0220
Fig. 1. Actuarial Kaplan-Meier survival plot for patients with available DS-GPA-class (n = 466). Differences between groups significant in pairwise comparison (Log rank,
p < 0.05).
Fig. 2. Actuarial Kaplan-Meier survival plot for patients with available EC-S (n = 157). Difference between all but groups 0 and 1 were significant in pairwise comparison (Log
rank, p < 0.05).
Table 3





Albumin <3.5 g/l 0.677 ± 0.403 1.97 0.093
LDH <250 U/l 0.072 ± 0.570 0.93 0.900
Treatment: Whole brain RT and no
(radio-)surgery
0.448 ± 0.246 1.57 0.068
DS-GPA: 2.5–3.0 1.295 ± 0.488 3.65 0.008
DS-GPA: 1.5–2.0 1.590 ± 0.483 4.90 0.001
DS-GPA: 0.5–1.0 2.181 ± 0.509 8.86 1.8  105
EC-S: 1 0.733 ± 0.449 0.48 0.1979
EC-S: 2 0.438 ± 0.724 1.55 0.545
EC-S: 3 0.297 ± 0.996 1.35 0.766
Table 4
Calculation of the combined EC-DS-GPA score.
DS-GPA EC-S
0 1 2 3
1 2 2 2 3
2 2 2 2 3
3 1 1 1 3
4 0 0 1 3
18 V. Lewitzki et al. / Clinical and Translational Radiation Oncology 16 (2019) 15–20Given the selection of both DS-GPA and EC-S into the final Cox
model, we heuristically combined both scores into a new ‘‘EC-GPA”
score with 4 categories (Table 4). Stratification of the 134 patientsfor which the new EC-GPA combination could be calculated
resulted in a clear separation of the survival curves (Fig. 3). The
hazard ratios of EC-GPA classes 1, 2 and 3 compared to class 0 were
4.84 (95% CI 1.42–16.46), 9.26 (2.83–29.97) and 31.64 (8.36–
119.76). Furthermore, with a CPE = 0.6355 ± 0.0230 the discrimina-
tion between the four prognostic groups was slightly increased
compared to the EC-S alone (CPE = 0.6258 ± 0.0220).
Fig. 3. Actuarial Kaplan-Meier survival plot for patients with ES-GPA-score (n = 134). Difference between all groups significant in pairwise comparison (Log rank, p < 0.05).
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A problem of proper patient and/or therapy selection has not
lost its importance since the beginning of local therapy of brain
metastasis. Selecting patients who have a chance to derive any
benefit from antitumor treatment is a prerequisite for omitting
unneeded treatment of those who have very limited survival
prognosis.
Some discouraging results of more aggressive local treatment of
brain metastases [14,15] challenged clinicians and statisticians.
Several methodologies on the way to prognostic tools for discrim-
ination of patient populations benefiting from more aggressive
treatment were developed [2,16] and validated [17–19].
Despite the validation of the RPA score we believe that it is not
helpful in answering any of the above questions. Sperduto et al.
modified the original GPA score obviously due to the need to bet-
ter stratify patients with brain metastases. The DS-GPA and
finally Lung-molGPA [20] and Melanoma-molGPA [21] scores
were developed and externally validated [19]. Nevertheless, even
these most recent scores have limited ability of reliably predicting
individual patient prognosis, sometimes classifying several long
term survivors into the group with the worst prognosis and vice
versa [21].
The role of extracranial factors such as performance status,
extent of extracranial metastases or control of the primary tumor
provided some additional valuable information about an individ-
ual’s prognosis [22]. A further refinement of the individual progno-
sis within the group of patients with very limited survival was
possible after inclusion of such widely available and cheap bio-
chemical surrogate parameters such as LDH and albumin [6].
The application of the EC-S to our data yielded similar results as
in the original derivation study by Nieder et al. [6]. First, with the
exception of the fairly good prognosis class 1, the EC-S appeared
well calibrated with median OS differences between our data and
the derivation data not larger than 1.1 months (Table 2). Second,
the EC-S had the highest discriminatory power as judged by Gönen
& Heller’s CPE. Third, the EC-S performed better than the RPA or
DS-GPA score in separating the group of patients with very poor
prognosis. However, in contrast to the DS-GPA score, the EC-S
was not able to separate the two groups of patients with a good
and fairly good prognosis in our data. This indicates some miscal-
ibration of the model underlying the EC-S for patients with morefavorable prognoses, so that survival predictions for new patients
are not necessarily reliable.
In building a multivariable prognostic Cox regression model on
our dataset, the RPA score was not selected as a prognostic factor,
while both the DS-GPA and EC-S were. Due to these findings we
pursued the idea of combining these two scores. We built 4 classes
in the collective of 134 patients with both known DS-GPA and EC-S
as displayed in Table 4. Application of the new combined score (EC-
GPA) resulted in a clear separation of the survival curves (Fig. 3)
and yielded slightly better discrimination between prognostic
groups than either the DS-GPA or EC-S alone, although the CPEs
of the EC-S and EC-GPA scores overlap within their uncertainties
due to the small sample size. We believe that, although acquired
heuristically, the EC-GPA score combination could be a good prog-
nostic tool which should be evaluated in future studies using larger
combined or independent datasets.
It is obvious that the paradigm of reserving stereotactic radio-
surgery for treating patients with the most favorable prognoses
changed over time. Low toxicity and wide availability of stereotac-
tic radiosurgery led to its more frequent application and omission
of WBRT [23] despite still controversial evidence for a clinical ben-
efit and clear concerns from detailed analysis of available random-
ized trials [24,25]. Prognostic scores were not analyzed in the
EORTC 22952–26001 trial, and only the RPA-score was used in
the trial of Yamamoto et al. The stratification according to GPA
score in the secondary analysis of Aoyama et al. demonstrated
clear benefit of WBRT in combination with stereotactic radio-
surgery in the group with best prognosis also in terms of OS.
Since the publication of the QUARTZ-trial there is a good level of
evidence that in preselected patients the use of very hypofraction-
atedWBRT has a limited effect on OS and quality of life [26]. Due to
several limitations of the trial such as intention-to-treat analysis
(ca. 20% of patients in the WBRT group did not receive WBRT), a
low treatment dose of 20 Gy, an obvious negative selection of
patients in both groups and more aggressive antitumor therapy
in the control arm there are still some questions about its practice
changing role. Despite the main conclusion of this trial, younger
patients did derive a clear benefit from WBRT in terms of overall
survival. GPA was not a significant variable in the survival analysis,
probably because of the limited number of patients with a high
score and limited statistical power to address this research
question.
20 V. Lewitzki et al. / Clinical and Translational Radiation Oncology 16 (2019) 15–20Our study shows that incorporation of extracranial factors into
a prognostic model significantly improves discriminatory power.
Nevertheless, our study has some limitations due to its retrospec-
tive nature and limited sample size, especially for the subset of
patients for which the EC-S could be calculated. Furthermore, it
was not planned a priori to develop a new prognostic score – the
combination of DS-GPA and EC-S was rather a data-driven heuris-
tic approach for improving the discrimination of various patient
groups with distinctly different prognoses. Due to the limited data
quality associated with the retrospective nature of this study, the
ad-hoc definition of the combined EC-GPA score should be seen
as a limitation. We prefer to consider the EC-GPA score as a hypo-
thetical possible way for further refinement of both the DS-GPA
and EC-S that should however be evaluated in future studies.
5. Conclusions
In conclusion, our study provides an independent validation of
the prognostic EC-S developed by Nieder et al. [6]. Their prognostic
model which is based solely on extracranial factors appeared to
have a higher external validity than both the RPA and DS-GPA
scores when applied to the unselected patients from our hospital.
It was also the best prognostic model for defining the patients
who obviously did not benefit from RT of brain metastases at least
in terms of OS. The combination of the EC-S with the established
DS-GPA score resulted in a slight gain of discriminatory ability.
Further validation of the EC-S and the new EC-GPA score will be
pursued in an ongoing analysis of combined patient cohorts from




[1] Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive
partitioning analysis (RPA) of prognostic factors in three Radiation Therapy
Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys
1997;37:745–51.
[2] Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic
index and comparison to three other indices for patients with brain
metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat
Oncol Biol Phys 2008;70:510–4. https://doi.org/10.1016/j.ijrobp.2007.06.074.
[3] Nieder C, Mehta MP, Geinitz H, Grosu AL. Prognostic and predictive factors in
patients with brain metastases from solid tumors: a review of published
nomograms. Crit Rev Oncol Hematol 2018;126:13–8. https://doi.org/10.1016/
j.critrevonc.2018.03.018.
[4] Nieder C, Mehta MP. Prognostic indices for brain metastases–usefulness and
challenges. Radiat Oncol. 2009;4:10. https://doi.org/10.1186/1748-717X-4-10.
[5] Feliu J, Jimenez-Gordo AM, Madero R, Rodriguez-Aizcorbe JR, Espinosa E,
Castro J, et al. Development and validation of a prognostic nomogram for
terminally ill cancer patients. J Natl Cancer Inst 2011;103:1613–20. https://
doi.org/10.1093/jnci/djr388.
[6] Nieder C, Marienhagen K, Dalhaug A, Aandahl G, Haukland E, Pawinski A.
Prognostic models predicting survival of patients with brain metastases:
integration of lactate dehydrogenase, albumin and extracranial organ
involvement. Clin Oncol (R Coll Radiol) 2014;26:447–52. https://doi.org/
10.1016/j.clon.2014.03.006.
[7] Rades D, Gerdan L, Segedin B, Nagy V, Khoa MT, Trang NT, et al. Brain
metastasis. Prognostic value of the number of involved extracranial organs.
Strahlenther Onkol 2013;189:996–1000. https://doi.org/10.1007/s00066-013-
0442-y.[8] Gerdan L, Segedin B, Nagy V, Khoa MT, Trang NT, Schild SE, et al. Brain
metastasis from non-small cell lung cancer (NSCLC): prognostic importance of
the number of involved extracranial organs. Strahlenther Onkol
2014;190:64–7. https://doi.org/10.1007/s00066-013-0439-6.
[9] Nieder C, Marienhagen K, Thamm R, Astner ST, Molls M, Norum J. Prediction of
very short survival in patients with brain metastases from breast cancer. Clin
Oncol (R Coll Radiol) 2008;20:337–9. https://doi.org/10.1016/
j.clon.2008.03.005.
[10] Gonen M, Heller G. Concordance probability and discriminatory power in
proportional hazards regression. Biometrika 2005;92:965–70. https://doi.org/
10.1093/biomet/92.4.965.
[11] Royston P, Altman DG. External validation of a Cox prognostic model:
principles and methods. BMC Med Res Method 2013;13:33. https://doi.org/
10.1186/1471-2288-13-33.
[12] Tibshirani R. The lasso method for variable selection in the Cox model. Stat
Med 1997;16:385–95.
[13] Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a
multivariable prediction model for Individual Prognosis or Diagnosis
(TRIPOD): the TRIPOD statement. J Clin Epidemiol 2015;68:134–43. https://
doi.org/10.1016/j.jclinepi.2014.11.010.
[14] Hoskin PJ, Crow J, Ford HT. The influence of extent and local management on
the outcome of radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys
1990;19:111–5.
[15] Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, et al. A
randomized trial to assess the efficacy of surgery in addition to radiotherapy in
patients with a single cerebral metastasis. Cancer 1996;78:1470–6.
[16] Curran Jr WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al.
Recursive partitioning analysis of prognostic factors in three Radiation
Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst
1993;85:704–10.
[17] Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive
partitioning analysis (RPA) classification for brain metastases. Int J Radiat
Oncol Biol Phys 2000;47:1001–6.
[18] Videtic GM, Adelstein DJ, Mekhail TM, Rice TW, Stevens GH, Lee SY, et al.
Validation of the RTOG recursive partitioning analysis (RPA) classification for
small-cell lung cancer-only brain metastases. Int J Radiat Oncol Biol Phys
2007;67:240–3. https://doi.org/10.1016/j.ijrobp.2006.08.019.
[19] Nieder C, Hintz M, Oehlke O, Bilger A, Grosu AL. Validation of the graded
prognostic assessment for lung cancer with brain metastases using molecular
markers (lung-molGPA). Radiat Oncol 2017;12:107. https://doi.org/10.1186/
s13014-017-0844-6.
[20] Sperduto PW, Yang T, Beal K, et al. Estimating survival in patients with lung
cancer and brain metastases: an update of the graded prognostic assessment
for lung cancer using molecular markers (lung-molgpa). JAMA Oncol
2017;3:827–31. https://doi.org/10.1001/jamaoncol.2016.3834.
[21] Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, et al.
Estimating survival in melanoma patients with brain metastases: an update of
the graded prognostic assessment for melanoma using molecular markers
(melanoma-molGPA). Int J Radiat Oncol Biol Phys 2017;99:812–6. https://doi.
org/10.1016/j.ijrobp.2017.06.2454.
[22] Nieder C, Norum J, Dalhaug A, Aandahl G, Engljahringer K. Best supportive care
in patients with brain metastases and adverse prognostic factors:
development of improved decision aids. Support Care Cancer
2013;21:2671–8. https://doi.org/10.1007/s00520-013-1840-5.
[23] Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al.
Stereotactic radiosurgery for patients with multiple brain metastases
(JLGK0901): a multi-institutional prospective observational study. Lancet
Oncol 2014;15:387–95. https://doi.org/10.1016/s1470-2045(14)70061-0.
[24] Aoyama H, Tago M, Shirato H, Japanese Radiation Oncology Study Group I.
Stereotactic radiosurgery with or without whole-brain radiotherapy for brain
metastases: secondary analysis of the JROSG 99-1 randomized clinical trial.
JAMA Oncol 2015;1:457–64. https://doi.org/10.1001/jamaoncol.2015.1145.
[25] Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al.
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or
surgical resection of one to three cerebral metastases: results of the EORTC
22952-26001 study. J Clin Oncol 2011;29:134–41. https://doi.org/10.1200/
JCO.2010.30.1655.
[26] Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al.
Dexamethasone and supportive care with or without whole brain
radiotherapy in treating patients with non-small cell lung cancer with brain
metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ):
results from a phase 3, non-inferiority, randomised trial. Lancet
2016;388:2004–14. https://doi.org/10.1016/S0140-6736(16)30825-X.
